Clinical Trial Update: Long-Term TARP Vaccination Using a Multi-Epitope TARP Peptide Autologous Dendritic Cell Vaccination in Previously Vaccinated Men on NCI 09-C-0139 [Phase 2]

View source ↗

Summary

Phase 2 trial update on long-term TARP peptide autologous dendritic cell vaccination for prostate cancer; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Multi-Epitope TARP Peptide Autologous Dendritic Cell Vaccine (TARP peptide autologous dendritic cell vaccine)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Prostatic Neoplasms, Neoplasms of Prostate | Phase 2 | Status: COMPLETED | Results posted: 2022-09-15